30th October, 2025

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001
Scrip Code: 500087

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg

Sub: <u>Press Release</u>

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Press Release dated 30th October, 2025.

Kindly take the above information on record.

Thanking you,

Yours faithfully,
For **Cipla Limited**

RAJENDRA CHOPRA
Digitally signed by RAJENDRA CHOPRA
Date: 2025.10.30 13:37:11 +05'30'

Rajendra Chopra
Company Secretary

Encl: As above

Prepared by: Pavankumar Yadav

Cipla

Q2 FY26 Results
Highest-Ever Quarterly Revenue with Robust EBITDA Margin at 25%

	Income from Operations	EBITDA	PAT
Q2 FY26:	INR 7,589 Cr 8% YoY	INR 1,895 Cr (25%) 0.5% YoY	INR 1,351 Cr (18%) 4% YoY

Mumbai, October 30, 2025: Cipla Limited (BSE: 500087, NSE: CIPLA) today announced its unaudited consolidated financial results for the quarter ended September 30th, 2025.

Key Highlights for the Quarter

- **One-India**: One India Business delivered a growth of 7% YoY for the quarter. Overall Chronic mix improved to 61.8% in the market#.
- **North America:** Delivered quarterly revenue of $ 233 Mn supported by traction in differentiated assets.
- **One Africa:** Growth trajectory continued with overall revenue growth at 5% YoY in USD terms. Prescription business ranked No. 2 in the market*.
- **Emerging Markets and Europe:** Posted a solid revenue growth of 15% YoY in USD terms.
- **R&D investments:** Stood at INR 539 Cr or 7.1% of sales, driven by product filings and development efforts.
- **Strong net cash**: Net cash position of INR 9,901 Cr; Debt primarily includes lease liabilities and working capital requirements.

*#Market data as per IQVIA MAT Sep'2025 *Market data as per IQVIA MAT Aug'2025*

"I am pleased to share that we continue to make considerable progress across our focused markets. In Q2FY26, we delivered our highest-ever quarterly revenue of INR 7,589 Cr, with a robust EBITDA margin of 25%. What makes this performance commendable is the breadth and balance of our growth, driven by contributions across all our focused markets. Our One-India business grew at 7% YoY. Key therapies in Branded Prescription business continued to deliver strong market growth and with the launch of Yurpeak® (Tirzepatide), we mark a pivotal step into obesity care through our strategic partnership with Eli Lilly. Trade Generics recorded a double-digit growth and Anchor brands of Consumer Health Business maintained leadership position. With a positive traction in our differentiated assets, the US business posted a revenue of $ 233 Mn during the quarter. In Q3 FY26, gRevlimid is expected to have a small contribution to the US revenue, with the base business expected to continue growing. Upcoming launches, subject to USFDA approvals, are expected to alleviate gRevlimid revenue decline over the next four quarters, though there may be a timing gap before the full benefit is realized. In One Africa, we achieved a healthy growth of 5% YoY in USD terms. Emerging Markets and Europe delivered a solid revenue growth of 15% YoY in USD terms on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front. "

Umang Vohra
MD and Global CEO, Cipla Ltd

For Queries Contact:

Corporate Communications
Heena Kanal
CorpComm@cipla.com

Investor Relations
Diksha Maheshwari
Investor.Relations@cipla.com

Cipla Ltd.
Cipla House,
Peninsula Business Park,
Ganpatrao Kadam Marg,
Lower Parel, Mumbai-400013

Market Updates

- **One India Business**

Branded Prescription:
Key therapies like Urology, Cardiac, Anti-diabetes and Dermatology grew at strong double-digit market growth, with the overall Chronic mix being improved to 61.8%. Foracort ranked No.1 Brand in the IPM as per IQVIA MAT Sep'25.

Trade Generics:
The business recorded strong double-digit growth. The performance was supported by execution excellence in key therapies, new introductions and technological interventions. The business launched 6 new products in Q2 FY26, including entry into Orthocare to expand therapy coverage.

Consumer Health:
Anchor brands of Nicotex, Omnigel and Cipladine maintained leadership positions in their respective market segments.

- **North America**

The North America business delivered quarterly revenue of $ 233 Mn, driven by the strong performance of differentiated assets. Albuterol ranked No. 1 in the overall U.S. Albuterol MDI market, with a 22% market share*. Lanreotide also performed well, achieving a 22% market share** during the quarter. A key milestone during this quarter was the launch of Filgrastim, the first biosimilar introduced in the U.S. market, marking a strategic entry into high-potential segments. The business also received the approval for the generic Glucagon Injection during the quarter.

- **One Africa**

One Africa recorded a healthy growth of 5% YoY in USD terms. In Private Market, secondary growth was at 6.2% versus the market** growth of 4.7%. South Africa overall private market ranked No. 3 in the market with the prescription business maintaining its No.2 position. This growth was propelled by advancement in key therapies, tender business as well as new launches.

- **Emerging Markets and Europe**

Deep market focus strategy in Emerging Markets and Europe has laid a solid foundation, with the business delivering a solid growth of 15% YoY in USD terms with an uptick in both DTM and B2B categories, along with sustained overall margins.

Market data as per IQVIA week ending 19th Sep'25 |** Market data as per IQVIA MAT Aug'25

QUARTERLY BUSINESS WISE SALES PERFORMANCE

Business (In INR Cr)	Q2FY26	Q2FY25	Y-o-Y Growth
India (Rx + Gx + CHL^)	3,146	2,948	*7%*
North America	2,039	1,986	*3%*
One Africa#	1,178	1,068	*10%*
South Africa	901	799	*13%*
Emerging Markets and Europe	967	806	*20%*
API	148	160	*-7%*
Others	111	83	*34%*
Total	7,589	7,051	8%

^ CHL – Cipla Health limited | # Includes South Africa, North Africa, Sub-Saharan Africa and Cipla Global Access

CONSOLIDATED PROFIT & LOSS STATEMENT

In INR Cr	Q2FY26	Q2FY25	Y-o-Y Growth
Total Income from Operations	**7,589**	**7,051**	*7.6%*
EBITDA	**1,895**	**1,886**	*0.5%*
% of Income from Operations	*25.0%*	*26.7%*	
PAT	**1,351**	**1,303**	*3.7%*

BALANCE SHEET

Key Balance Sheet Items (INR Cr)	Sep-25	Sep-24
Equity	33,025	28,456
Total Debt#	467	461
Inventory	6,160	5,573
Cash and Cash Equivalents*	10,368	8,412
Trade Receivables	6,902	5,588
Trade Payables	3,035	2,675
Net Tangible Assets	6,996	6,329
Goodwill and Intangibles	5,374	5,111

*#Total debt includes lease liabilities and borrowings | * Cash & cash equivalents include current investments, fixed deposits, margin deposits and excluding unclaimed dividend balances*

Announcement

Cipla to release Q2FY26 unaudited Financial Results on October 30, 2025

Date: October 30, 2025

- **1600 hrs IST – EARNINGS CONFERENCE CALL**
  The Company will host an earnings conference call at 1600 hrs IST (1830 hrs SST/HKT, 1030 hrs GMT, 0630 hrs US ET), during which the leadership team will discuss financial performance and take questions. A transcript of the conference call will be available at www.cipla.com.

Earnings Conference Call Dial-in Information

Date and Time	**October 30, 2025** at 1600 – 1700 hrs IST 1830 – 1930 hrs SST/HKT 1030 – 1130 hrs GMT 0630 – 0730 hrs US ET
Dial-in Numbers	
Universal Access	Primary Access: **(+91 22 6280 1562)** **(+91 22 7115 8387)**
Diamond pass link	Click here to register
Toll Free Number	USA: **18667462133** UK: **08081011573** Hong Kong: **800964448** Singapore: **8001012045**

ABOUT CIPLA LTD

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Sep'25), 2nd Largest in the pharma prescription market in South Africa (IQVIA MAT Aug'25), and 4th largest by prescription in the US Gx (Repulses + MDI) products (IQVIA MAT Aug'25). For over eight decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

Disclaimer: Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, fluctuation in earnings, foreign exchange rates, our ability to manage international operations and exports, our exposure to market risks as well as other risks. Cipla Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.